Dermal Fillers: What They Are, Cost, Results and Finding an Injector

FDA's definition is the plainest starting point.

Dermal fillers — also called injectable implants, soft tissue fillers, lip and facial fillers, or wrinkle fillers — are medical device implants approved by the FDA to help create a smoother and/or fuller appearance in the face, including the nasolabial folds (smile lines), cheeks, chin, lips and the back of the hands.

They are regulated as devices and approved through premarket approval (PMA), and each approval names the specific areas that product may be injected into.

That is what "on-label" means for a filler: a product placed in an area its own approval names is on-label there, and the same product used somewhere else is off-label.

Age is part of the approval picture too — FDA states fillers are approved for adults aged 22 or older (over 21), with individual product labels setting the exact age.

Mechanically the treatment is direct: the product is placed into the treatment area, where it sits in the tissue and creates the smoother or fuller appearance the approval describes.

Allergan says its Juvéderm products are injected with a needle or a cannula, and that Juvéderm results are visible immediately after treatment — a manufacturer statement worth reading with the side-effect list in mind, because FDA counts swelling among the common risks and says such effects usually appear soon after injection.

FDA sorts filler materials into absorbable (temporary) ones — hyaluronic acid, calcium hydroxylapatite (CaHA) and poly-L-lactic acid (PLLA) — and one non-absorbable (permanent) material, PMMA microspheres in bovine collagen.

FDA says it has approved only one product made from a material the body does not absorb. "Biostimulator" is marketing shorthand for those two absorbable, non-HA materials — Galderma, Sculptra's maker, calls its PLLA filler a "biostimulatory aesthetic injectable" — so the comparison that matters is hyaluronic acid against CaHA and PLLA.

Hyaluronic acid is a sugar (polysaccharide) naturally present in skin and cartilage, per FDA.

The HA in fillers is sourced from bacteria or rooster combs and is often chemically crosslinked to make it last longer in the body.

Timing is where their published materials draw the sharpest contrast: Allergan says Juvéderm results are visible immediately after treatment, while the Sculptra label describes the opposite pattern for its product — the immediate fullness after a session is mostly water swelling that resolves within hours to a few days, after which the original deficiency reappears and correction develops gradually.

The Sculptra label says the area should be under-corrected, with at least 3 to 4 weeks before reassessment.

Sculptra itself is a freeze-dried poly-L-lactic acid powder in 367.5 mg single-patient, single-session vials that must be reconstituted with sterile water before injection.

The approvals differ just as much. Radiesse, the CaHA filler (Merz), is approved for moderate to severe facial wrinkles and folds such as nasolabial folds (2006), HIV facial lipoatrophy, hand volume loss (2015), jawline contour for the Radiesse (+) version (2021) and — diluted 1:2 with saline — décolleté wrinkles in patients 22 or older (2026).

Sculptra (PLLA, Galderma) was approved in 2004 for HIV-associated facial fat loss, in 2009 (as Sculptra Aesthetic) for shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in immune-competent people, and in 2023 for fine lines and wrinkles in the cheek region.

Those are its only indications: Sculptra's label states that safety and effectiveness have not been evaluated in larger amounts, at different frequencies or at sites other than its approved uses — which is what puts its much-discussed buttock, hip, temple and jawline uses off-label.

The permanent material stands apart: Bellafill — PMMA microspheres in bovine collagen, originally approved as ArteFill in 2006 for nasolabial folds — is the only permanent US filler under FDA's grouping.

It gained an indication for moderate to severe atrophic distensible cheek acne scars in patients over 21 in 2014, and FDA approved renaming it SANAE on 2026-08-07.

One material has no approval at all: FDA has NOT approved liquid silicone or silicone gel injection to fill wrinkles or augment tissue anywhere in the body.

FDA's overview describes fillers approved for the nasolabial folds, cheeks, chin, lips and the back of the hands, but the working map is more detailed, because approvals arrive one product and one area at a time.

Allergan, for example, describes its Juvéderm collection as six FDA-approved hyaluronic acid fillers covering cheeks, chin, temples, smile lines, lips, under-eyes and jawline — each product for its own labeled areas.

An area is on-label only for the products whose own approvals name it.

Here are example products whose approvals name each area, drawn from FDA premarket approval records dated 2026-10-12 — examples, not an exhaustive list of every approval on file.

For an area-by-area overview, see what areas dermal filler can treat.

Outside approvals like these, the map flips to off-label.

FDA's general filler page lists injecting the glabella (the area between the eyebrows), nose, periorbital area, forehead or neck as not FDA-approved uses — wording that predates the product-specific under-eye and neck-line approvals above, which is why an area can only be called on-label by naming the product.

A keyword scan of FDA's PMA file dated 2026-10-12 found no US face or hand filler approved for the nose, glabella, forehead, buttocks, hips or breasts.

For planning several face areas together, see what facial balancing with filler is.

On the body, FDA goes further: it recommends against using any dermal filler for body contouring, including increasing breast or buttock size, and says those uses are not FDA-approved.

Ask how any quote is built — per syringe, per vial or per treatment — because the unit behind the price changes what it means, and the unit itself varies: Revanesse Versa, Versa+ and Lips+ syringes are approved in both 1.0 mL and 1.2 mL sizes, so "one syringe" is not always 1 mL.

ASPS says dermal filler cost varies with the injector's expertise and qualifications, the type of procedure, the time and effort required and the geographic location of the office — and that health insurance does not cover dermal fillers.

National figures exist, but each measures something different.

ASPS lists average costs of $715 for hyaluronic acid fillers, $901 for non-hyaluronic acid fillers (e.g. Radiesse, Sculptra, Bellafill) and $743 for lip augmentation with filler — average fees reported by ASPS member plastic surgeons, not med spa prices, and the page does not state the data year or whether each figure is per syringe or per procedure.

Allergan's consumer site says Juvéderm treatment can range from $600 to $1,400 depending on product and provider.

That is a manufacturer's range — not an average and not a quote.

A surgeons'-fee average and a maker's range measure different things, so neither one is a price you can book, and ASPS's 2025 statistics release publishes no procedure counts or average fees for minimally invasive treatments at all; it reports hyaluronic acid fillers as 30% of minimally invasive treatments (neuromodulators about half) and lip augmentation as 23% of HA filler treatments.

Manufacturer rewards programs attach to filler brands.

Allergan's Allē program gives 100 points = $10 toward qualifying treatments including Juvéderm, and Galderma's ASPIRE program (Restylane, Sculptra and other Galderma products) offers a $20-off welcome reward, 100 points = $10 and up to 600 points per visit.

Program terms change, so check them before you book.

FDA's material-level estimates are the most general figures: 6 to 12 months for hyaluronic acid, 18 months for calcium hydroxylapatite, and up to 2 years for PLLA, whose results appear gradually over several weeks.

These are estimates for the materials — not promises for any product, area or person.

For a fuller breakdown, see how long dermal fillers last.

Manufacturers publish their own, more specific figures, each tied to one product in one area.

Allergan's stated maximums, "with optimal treatment": Voluma XC cheeks up to 2 years, Voluma XC chin up to 1 year, Voluma XC temples up to 13 months, Vollure XC smile lines up to 18 months, Ultra Plus XC smile lines up to 1 year, Volux XC jawline up to 1 year, and Volbella XC under-eyes up to 1 year.

These are manufacturer claims — not label data and not averages.

The one permanent product is the exception that proves the rule about reading figures by their source: Bellafill (renamed SANAE in 2026) is made of PMMA, a material the body does not absorb, which is why FDA counts it as the only permanent US filler.

Permanence is not the same as removability — FDA says removing filler can require injections, surgery or other interventions with their own risks, and may be difficult or impossible, especially for permanent fillers or fillers not made of hyaluronic acid.

One more finding surprises people: the visible effect and the physical product are not the same thing.

An MRI study of 33 patients found mid-face HA filler still detectable in all of them at least 2 years after injection, with some filler visible 8 to 15 years later — evidence that HA can persist in tissue long after the visible effect fades.

FDA's risk list runs in three tiers.

Common risks: bruising, redness, swelling, pain, tenderness, itching and rash.

Less common: nodules or granulomas, infection, allergic reaction and necrosis.

Rare but reported: anaphylaxis, migration of filler, permanent hard nodules, blindness, stroke and death.

On timing, FDA says side effects such as swelling and bruising usually appear soon after injection and many resolve in days to weeks — but some may appear weeks, months or years later.

For more on each one, see dermal filler side effects.

Emergency readiness is part of what FDA expects on the other side of the needle.

It tells injectors to know the signs of intravascular injection, to keep an updated plan detailing how a patient would be treated should it occur, and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

Expert reviews go further, naming prompt recognition and immediate hyaluronidase as the mainstay of treating HA-filler vascular occlusion and recommending a "filler crash cart" and an in-office action protocol with agents readily available — professional guidance, not an FDA rule, and hyaluronidase breaks down hyaluronic acid fillers only.

Who should be cautious: FDA says filler safety is unknown during pregnancy and breastfeeding, in people under 22 and in people prone to keloid or hypertrophic scarring, and that treatment should be delayed if the skin is inflamed or infected.

FDA also says to tell the provider about bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria.

Two evidence gaps FDA names: the safety of fillers combined with neuromodulators (e.g. Botox) or other treatments, and of repeated use over a long period, has not been evaluated in controlled clinical studies.

What about undoing a result you do not like?

Hyaluronidase dissolves hyaluronic acid fillers only — Cleveland Clinic says dissolving usually takes one to two visits, with full results in up to two weeks, and that providers ask about bee-sting allergy before using it.

Even that everyday use is off-label: hyaluronidase products such as Hylenex are FDA-approved only to aid subcutaneous fluid administration, to increase the dispersion and absorption of other injected drugs, and in subcutaneous urography.

FDA adds that removing filler can be difficult or impossible, especially for fillers not made of HA, and Allergan's own safety information states that the effectiveness of removal of any dermal filler has not been studied.

FDA's advice is concrete: choose a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection — and treat the appointment as what FDA says it is. "Having filler injected should be considered a medical procedure, not a cosmetic treatment."

Who may hold the syringe is decided state by state.

AmSpa, the American Med Spa Association, describes a common delegation model: NPs injecting with documented training under a collaborative agreement or full practice authority, and RNs — and in some states LPNs/LVNs or medical assistants — injecting only with documented training, after a patient exam and treatment order from a physician (or delegated PA/NP), with the physician on site or promptly reachable.

That is a trade association's general description, not each state's law, and it does not hold everywhere — so it is worth checking your state's medical or nursing board rules before you book.

The preparedness facts give you two questions any consultation should answer easily: whether the injector has a plan for treating an intravascular injection, and whether treatment agents are readily available in the office.

FDA's warnings about shortcuts close the loop: needle-free devices such as "hyaluron pens" are not approved for injecting dermal fillers, no filler is approved for over-the-counter use, and people should not inject themselves or buy filler online.

FDA has also warned that unapproved versions of Juvéderm (Juvederm Ultra 2, 3 and 4) have been sold in the US, including online, and should not be used.

Prices, products and injector credentials change clinic by clinic and city by city — ASPS explicitly lists the geographic location of the office among what drives filler cost — so the useful comparison work is local.

Before booking anywhere, it helps to have four things in writing: the exact product and whether its approval covers the area, who will inject and with what license and training, the price per syringe or vial and the total including any touch-up, and the clinic's plan for treating a vessel emergency.

Approval status is the check that catches the most marketing.

Labels are product-specific, so the same brand name can be on-label in one area and off-label in another; the question to ask is whether the exact product is approved for the exact area you are considering.

A clinic that names the product, points to its approval and tells you plainly when a use is off-label is showing you FDA's own framing — that filler is a medical procedure, not a cosmetic treatment.

Timing is the last piece.

FDA says side effects such as swelling and bruising usually appear soon after injection and many resolve in days to weeks, while some can appear weeks, months or years later — worth building a buffer before any fixed event, and worth discussing with the clinic you choose.